Anavex Life Sciences Corp (AVXL)

[makemydaze]

The presentation has a lot of info to decipher. One theme I see is they say if this happens -

"Disturbances along the Brain-Gut-Microbiota Axis including the CNS contribute to the pathogenesis of Alzheimer’s disease.

Alterations in the gut microbiota composition induce increased permeability of the gut barrier and immune activation leading to systemic inflammation which in turn may impair the blood-brain barrier and promote neuroinflammation, neural injury, and ultimately neurodegeneration.

The gut microbiota is known to upregulate local and systemic inflammation from pathogenic bacteria and synthesis of proinflammatory cytokines"

Then this could happen:

"The S1R agonist ANAVEX®2-73 could potentially normalize neuroinflammatory processes by several different mechanisms:

1. Reducing microglia over-activation
2. Reducing inflammatory cytokines
3. Increasing anti-inflammatory cytokines
4. Releasing protective factors, e.g. BDNF
5. Protect against inflammatory molecules"

https://www.anavex.com/wp-content/uploads/2019/07/Anavex-Microbiota-Presentation-AAIC-July-2019-1.pdf

I do like the idea that they(Anavex and others) are looking into more of the why parts of neuro diseases.

Does this info fit into what another company says is their goal?

"Today's opening of G2D2 reaffirms our relentless pursuit to discover innovative medicines that may someday offer a complete treatment regimen that is preventative, restorative and regenerative to help address the devastation patients and families experience living with these debilitating diseases."

https://www.prnewswire.com/news-releases/eisai-commemorates-opening-of-center-for-genetics-guided-dementia-discovery-in-cambridge-massachusetts-300880901.html